REG - IXICO plc - IXICO chosen for new Phase II AD study

IXICOAnnouncement

10/03/2021 07:01

RNS Number : 6988R
  
IXICO plc
  
10 March 2021
  
 

IXICO plc
("IXICO" or the "Company")
 
IXICO chosen for new Phase II Alzheimer's disease study
 
IXICO plc (AIM:IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been selected by a current mid-sized biopharmaceutical client to support the company's Phase II Alzheimer's disease clinical trial. Conducted across 125 sites in 10 countries over 5 years, the study will investigate an anti-Tau antibody treatment for individuals with prodromal and mild Alzheimer's disease (AD).  For the study, IXICO will provide advanced neuroimaging solutions involving structural magnetic resonance imaging (MRI), volumetric MRI (vMRI), diffusion MRI (dMRI) and arterial spin labelling (ASL).
 
AD affects approximately 50 million people worldwide with no available therapies to address the underlying disease pathology. Biopharmaceutical companies are responding to this challenge with innovations in clinical trials and treatment targets in their AD pipelines. These include increased diversification of drug candidates by investigating disease-modifying agents targeting pathways other than the historical focus area of amyloid. This new study, which follows on from the AD study award by Cyclerion Therapeutics, Inc announced on 2 March 2021, further demonstrates the important growing industry trend of target diversification in AD drug development.  
 
Whilst this contract does not change management's expectations of financial performance for the year, it adds to the Company's strong order book and further increases visibility of future revenues.
 
Lammert Albers, Chief Commercial Officer of IXICO, commented:
"IXICO is delighted to be awarded the contract for this new Alzheimer's disease clinical trial. With less well-defined target biology, limited availability of biomarkers and higher risk of failure, drug development in Alzheimer's disease presents significant challenges for the industry. In turn, biopharmaceutical sponsors are responding with more disease-modifying treatment candidates and greater diversity of drug targets in AD pipelines.  We are proud to support sponsors in their tireless efforts to bring potential treatments for this devastating disease, and these recent awards reflect the confidence clients place in IXICO as the trusted neuroimaging partner for their Alzheimer's disease pipeline innovations."
 
For further information please contact:
 




IXICO plc


+44 (0)20 3763 7498




Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer


 




 


 




Cenkos Securities PLC (Nominated adviser and sole broker)


+44 (0)20 7397 8900




Giles Balleny / Max Gould (Corporate Finance)


 




Michael F Johnson / Russell Kerr (Sales)


 




 


 




Walbrook PR Ltd


+44 (0)20 7933 8780




Paul McManus / Lianne Cawthorne /


IXICO@walbrookpr.com




Alice Woodings
 


 



 
 
 
 
 



About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
 
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCFZGGFVLRGMZM